ZURICH, April 22 (Reuters) - Swiss drugmaker Roche (ROPC.S), opens new tab on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting ...

Corcept Therapeutics’ ALS drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate ...

Multiple sclerosis (MS) is most prevalent in Northern Europe and Canada, and more common in the northernmost latitudes. In ...

Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...

Roche (RHHBF) (RHHBY) has announced plans to seek regulatory review for an experimental therapy for multiple sclerosis, an autoimmune condition affecting the central nervous system, even as its ...

President Donald Trump has repeatedly said his deals with drugmakers would bring down prescription drug prices in the U.S. But a report released by Senate Democrats finds prices have continued to ...

Application Filed to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. The Swiss drugmaker Roche on Tuesday presented the latest data for its ...

Cannabis has been legalised for medial use since 2018 ...

Alembic Pharmaceuticals Limited ( (IN:APLLTD)) has issued an update. Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug ...

Patients with one of the deadliest cancers have been pleading for an unapproved treatment that may prolong their lives.

Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the ...